CASI Pharmaceuticals Inc.

NASDAQ: CASI · Real-Time Price · USD
2.35
0.41 (21.13%)
At close: Aug 15, 2025, 3:59 PM

CASI Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
28.54M 33.88M 43.11M 30.17M
Cost of Revenue
17.39M 13.83M 15.83M 12.56M
Gross Profit
11.15M 20.05M 27.28M 17.61M
Operating Income
-39.62M -25.08M -26.49M -35.28M
Interest Income
539K 614K 189K 321K
Pretax Income
-38.07M -26.29M -37.43M -35.84M
Net Income
-39.26M -26.94M -39.41M -37.77M
Selling & General & Admin
41.44M 41.84M 37.77M 38.47M
Research & Development
8.92M 9.86M 16M 14.42M
Other Expenses
407K -6.57M 44K n/a
Operating Expenses
50.77M 45.13M 53.77M 52.89M
Interest Expense
871K n/a 62K n/a
Selling & Marketing Expenses
17.87M 16.45M 14.33M 14.71M
Cost & Expenses
68.16M 58.96M 69.6M 65.45M
Income Tax Expense
1.19M -81K 1.98M 1.93M
Shares Outstanding (Basic)
15.34M 13.36M 13.65M 13.61M
Shares Outstanding (Diluted)
15.34M 13.36M 13.65M 13.61M
EPS (Basic)
-2.56 -2.02 -2.89 -2.78
EPS (Diluted)
-2.56 -2.02 -2.89 -2.78
EBITDA
-34.87M -21.54M -24.07M -32.75M
EBIT
-37.2M -25.28M -26.49M -35.22M
Depreciation & Amortization
2.33M 3.74M 2.42M 3.1M